Your browser doesn't support javascript.
loading
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer.
Tolmeijer, Sofie H; Boerrigter, Emmy; Sumiyoshi, Takayuki; Kwan, Edmond M; Ng, Sarah W S; Annala, Matti; Donnellan, Gráinne; Herberts, Cameron; Benoist, Guillemette E; Hamberg, Paul; Somford, Diederik M; van Oort, Inge M; Schalken, Jack A; Mehra, Niven; van Erp, Nielka P; Wyatt, Alexander W.
Afiliación
  • Tolmeijer SH; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Boerrigter E; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Sumiyoshi T; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Kwan EM; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Ng SWS; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Annala M; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Donnellan G; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Herberts C; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Benoist GE; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Hamberg P; Department of Medical Oncology, Franciscus Gasthuis & Vlietland, Rotterdam/Schiedam, the Netherlands.
  • Somford DM; Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands.
  • van Oort IM; Department of Urology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Schalken JA; Department of Urology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Mehra N; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • van Erp NP; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Wyatt AW; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Clin Cancer Res ; 29(15): 2835-2844, 2023 08 01.
Article en En | MEDLINE | ID: mdl-36996325
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias de la Próstata Resistentes a la Castración / ADN Tumoral Circulante Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias de la Próstata Resistentes a la Castración / ADN Tumoral Circulante Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos